Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System

Table 4

The association between different SGLT2 inhibitors and FG occurrence.

Drug		ROR	PRR	IC	EBGM
		(95% two-sided CI)	(^2)	(IC025)	(EBGM05)
Canagliflozin	190	18.76 (16.22, 21.70)	18.60 (3058.02)	4.17 (3.61)	18.00 (15.94)
Canagliflozin/metformin	9	20.12 (10.43, 38.81)	19.93 (161.61)	4.31 (2.24)	19.90 (11.48)
Dapagliflozin	96	22.89 (18.68, 28.04)	22.64 (1952.68)	4.48 (3.65)	22.27 (18.79)
Dapagliflozin/saxagliptin	0	—	—	—	—
Dapagliflozin/metformin	12	34.86 (19.69, 61.73)	34.28 (387.09)	5.10 (2.88)	34.21 (21.21)
Empagliflozin	209	46.70 (40.61, 53.70)	45.70 (8798.23)	5.46 (4.75)	44.02 (39.16)
Empagliflozin/linagliptin	10	23.82 (12.76, 44.46)	23.55 (215.66)	4.56 (2.44)	23.51 (13.95)
Empagliflozin/metformin	13	54.79 (31.56, 95.12)	53.36 (666.70)	5.73 (3.30)	53.24 (33.56)
Ertugliflozin	3	18.68 (5.99, 58.24)	18.51 (49.70)	4.21 (1.35)	18.50 (7.15)
Ertugliflozin/metformin	0	—	—	—	—
Ertugliflozin/sitagliptin	0	—	—	—	—
Ipragliflozin	0	—	—	—	—
Luseogliflozin	0	—	—	—	—
Tofogliflozin	0	—	—	—	—